BCM
AVTX icon

BlueCrest Capital Management’s Avalo Therapeutics AVTX Stock Holding History

BlueCrest Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12
Closed -$194K – 450
2019
Q1 		$194K Buy
12
+2
+20% +$29.9K 0.01% 962
2018
Q4 		$93K Buy
+10
New +$111K ﹤0.01% 770

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

BlueCrest Capital Management's AVTX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Avalo Therapeutics (AVTX) in Q2 2019, closing a stake of 12 shares — an estimated $194K sold.

BlueCrest Capital Management first reported a position in AVTX in Q4 2018 and held it in 2 quarters. The position peaked at $194K in Q1 2019. 36 funds tracked by Wall St. Rank hold AVTX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Avalo Therapeutics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 12 Avalo Therapeutics shares in Q2 2019, an estimated $194K.
  • BlueCrest Capital Management first reported a position in Avalo Therapeutics in Q4 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Avalo Therapeutics position peaked at $194K in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.